T14 Alzheimer's disease mechanism research
exploratoryresearch program · high · Thu May 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Define and validate T14, a 14-amino-acid peptide, as a toxic driver of neurodegeneration and an upstream mechanism in Alzheimer's disease.
Disease-mechanism research using published studies of T14 biology, including links to calcium influx, mTORC1 activation, impaired autophagy, beta-amyloid accumulation, age-dependent behavior, oxidative stress, and Alzheimer's pathology.
2024 publications reported evidence for a novel neuronal mechanism driving Alzheimer's disease upstream of amyloid and additional T14-related mechanistic findings.
Supplied evidence describes T14 as elevated in Alzheimer's brains, toxic in the adult brain, and a proposed primary driver of neurodegeneration.
NBP-14 Alzheimer's therapeutic program
preclinicaldrug program · high
Antagonize T14 activity to interrupt an Alzheimer's-associated toxic cascade and support early-stage intervention or prevention.
Cyclated T14 variant designed as a T14 receptor blocker; evaluated in preclinical models for antagonism of T14-induced toxicity and cognitive effects.
2026 publication evidence compares NBP14-derived approaches with NBP6B and small molecules; earlier supplied evidence says NBP14 produced cognitive benefits in a preclinical mouse model.
NBP14 is described as a T14 receptor blocker with cognitive benefits in a preclinical mouse model, but high molecular weight was noted as a potential translation limitation.
NBP-14 derivatives for diabetic retinopathy
undiscloseddrug program · medium
Apply NBP-14-derived therapeutic approaches to diabetic retinopathy.
Derivatives of NBP-14; specific intervention method and study design are not disclosed in the supplied material.
Listed in Neuro-Bio's pipeline as NBP-14 and derivatives for diabetic retinopathy.
NBP6B Alzheimer's therapeutic variant
preclinicaldrug program · high
Develop a shorter T14-antagonist therapeutic with improved efficacy and bioavailability for early-stage Alzheimer's intervention.
Shorter linear 6-mer peptide variant tested against T14-induced toxicity in PC12 calcium influx and cell viability assays, with alpha7 nicotinic acetylcholine receptor specificity assessment.
2026 publication reported comparison of NBP6B against two novel small molecules for antagonising T14-induced toxicity.
NBP6B showed greater potency and selectivity than the small molecules, with effective antagonism in the nanomolar range versus micromolar concentrations for the small molecules.
T14 nasal secretion lateral-flow antigen test
undisclosedbiomarker · high
Develop a pre-symptomatic biomarker diagnostic for T14 detection in nasal secretions.
Lateral-flow antigen test for T14 in nasal secretions.
Listed in Neuro-Bio's pipeline as an LFT/antigen test for T14 in nasal secretions.
T14 saliva immunodetection clinical diagnostic
undisclosedbiomarker · high
Develop a clinical diagnostic test for detecting T14 using saliva samples.
Clinical diagnostic test using immunodetection technology in saliva.
Listed in Neuro-Bio's pipeline as a saliva-based clinical diagnostic using immunodetection technology.
THK-117 anti-T14 monoclonal antibody
preclinicaldrug program · high
Develop a monoclonal antibody candidate for T14 detection and potential rescue from T14-induced toxicity in Alzheimer's disease.
Anti-T14 monoclonal antibody validation using T14 detection assays, PC12-cell toxicity rescue testing, and quantitative indirect conjugated T14 ELISA binding-affinity assays.
2026 publication identified THK-117 as the most promising antibody and a candidate for humanization.
THK-117 showed efficacy comparable to the Ab-19 polyclonal antibody, with manufacturing reproducibility, high binding specificity toward the T14 epitope, and a low EC50.
